Business
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore. Data to be presented will highlight the progress of SAB BIO
About this update from Sab Biotherapeutics, Inc.
[{"type":"image","alt":"SAB Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"SAB Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/e5f8996aaa758da6bd63f582a6d0edc0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nx_udecyR0_0bIWMMlxwug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5f8996aaa758da6bd63f582a6d0edc0","width":300,"height":123}},"lazy":false},{"type":"text","content":"MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore.","length":445,"tagName":"p"},{"type":"text","content":"Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including:","length":259,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 study data demonstrating immunomodulation without sustained lymphodepletion following dosing of SAB-142.","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 study data demonstrating a favorable safety profile for SAB-142, characterized as not causing serum sickness or anti-drug antibodies at the target dose.","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"“We are excited to share data at another major international conference to highlight the robust multi-specific mechanism of action of our lead program, SAB-142. Our presentations at ATTD-Asia continue to support the development of SAB-142 as a potential best-in-class immunotherapy, currently in Phase 2b clinical development for delaying the progress...